November 19, 2020

results from REMAP-CAP trial – tocilizumab for patients with severe COVID-19

The REMAP-CAP trial, which began investigating treatments for COVID-19 in March, has been trialling potential treatments in hospitalised patients with either moderate or severe COVID-19. On November 17th, the Data and Safety Monitoring Board (DSMB) informed the International Trial Steering Committee of results for lopinavir/ritonavir and tocilizumab in severe COVID-19.

Journalists dialled in to hear the researchers involved discuss these results, and what they mean for patients.

Speakers included:

Prof Anthony Gordon, Professor of Anaesthesia and Critical Care, NIHR Research Professor, Imperial College London and UK Chief Investigator of the REMAP-CAP trial

Dr Lennie Derde, Intensive Care Consultant and European Coordinating Investigator of the REMAP-CAP trial

Mr Paul Mouncey, Head of Research, Intensive Care National Audit & Research Centre (ICNARC)

This Briefing was accompanied by an SMC Roundup of Comments.